Business
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
NEWTON, Mass., May 23, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., May 23, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6 in Chicago, Illinois and the 2023 European Hematology Association (EHA) Hybrid Congress, being held June 8-11 in Frankfurt, Germany.\n\n \n \n \n \n \n \n\n \n\"We've made significant strides advancing our pipeline and demonstrating the potential benefit that XPO1 inhibition can deliver to patients with cancers characterized by high unmet needs,\" said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. \"The presentations at ASCO and EHA highlight our continued pursuit of transformative research to positively impact patients' lives and ultimately defeat cancer.\"\nDetails for the ASCO abstracts are as follows:\nAbstract Title\nPresentation Type\nAbstract #\nSession Date/Time\nMyelofibrosis\nSelinexor (SEL) plus Ruxolitinib (RUX) in JAK Inhibitor (JAKi) Treatment-Naïve Patients withMyelofibrosis: Updated results from XPORT-MF-034\nPoster\n \n \n7063\nMonday, June 5, 2023\n \n8:00am - 11:00am CDT / 9:00am – 12:00pm EDT\nEndometrial Cancer\nENGOT-EN20/GOG-3083/XPORT-EC-042 A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapyfor Patients with P53 Wild-Type, Advanced orRecurrent Endometrial Carcinoma\nPoster\n \nTPS5627\nMonday, June 5, 2023\n \n1:15pm - 4:45pm CDT / 2:15pm – 5:45pm EDT\nMultiple Myeloma\nEfficacy and Safety of 40 mg vs 60 mg Once Weekly Selinexor in Combination with Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM)40 mg vs 60 mg in RRMM\nOnline Abstract Publication\n \ne20006\nEffectiveness of Anti-B-cell Maturation Antigen (BCMA)-Targeting Therapy After Selinexor Treatment\nOnline Abstract Publication\n \ne20034\nDetails for the EHA abstracts are as follows:\nAbstract Title\nPresentation Type\nAbstract #\nSession Date/Time\nMyelofibrosis\nSelinexor (SEL) plus Ruxolitinib (RUX) in JAKInhibitor (JAKi) Treatment-Naïve Patients with Myelofibrosis: Updated results from XPORT-MF-034\nPoster\n \nP1020\nFriday, June 9, 2023 \n \n6:00pm – 7:00...